Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Basic): 2021-2024

Historic EPS (Basic) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $0.08.

  • ARS Pharmaceuticals' EPS (Basic) fell 160.00% to -$0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year decrease of 60.78%. This contributed to the annual value of $0.08 for FY2024, which is 114.04% up from last year.
  • As of FY2024, ARS Pharmaceuticals' EPS (Basic) stood at $0.08, which was up 114.04% from -$0.57 recorded in FY2023.
  • ARS Pharmaceuticals' EPS (Basic)'s 5-year high stood at $0.08 during FY2024, with a 5-year trough of -$0.87 in FY2022.
  • Over the past 3 years, ARS Pharmaceuticals' median EPS (Basic) value was -$0.57 (recorded in 2023), while the average stood at -$0.45.
  • Per our database at Business Quant, ARS Pharmaceuticals' EPS (Basic) dropped by 24.29% in 2022 and then skyrocketed by 114.04% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' EPS (Basic) (Yearly) stood at -$0.70 in 2021, then dropped by 24.29% to -$0.87 in 2022, then soared by 34.48% to -$0.57 in 2023, then surged by 114.04% to $0.08 in 2024.